Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Non-Hodgkin 4 Lymphoma, Follicular 4 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma, B-Cell 2 Lymphoma 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Leukemia, Prolymphocytic 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Dendritic Cell Sarcoma, Interdigitating 1 Burkitt Lymphoma 1 Arthritis, Rheumatoid 1

Interventions

Adalimumab 13 Methotrexate 11 Etanercept 10 Rituximab 5 Abatacept 5 tocilizumab 4 olokizumab 4 tofacitinib 3 golimumab 3 Infliximab 3 Tumor Necrosis Factor Inhibitors 2 Saline Solution 2 RC-18 2 Nivolumab 2 Leflunomide 2 Certolizumab Pegol 2 Antirheumatic Agents 2 veltuzumab 1 upadacitinib 1 secukinumab 1 sarilumab 1 mavrilimumab 1 entecavir 1 cabozantinib 1 baricitinib 1 andecaliximab 1 Vitamin D 1 Vaccines 1 TACI receptor-IgG Fc fragment fusion protein 1 Syringes 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Arthritis, Rheumatoid × veltuzumab × Clear all

NCT01390545 2016-04-13

VELVET

Takeda

Phase 2 Terminated

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡